Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Conformal Radiotherapy. Found 55 abstracts

no pagination
Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, Todor DA, Simone NL, Hayes SB, Woodward WA, McCormick B, Cohen RJ, Sahijdak WM, Canaday DJ, Brown DR, Currey AD, Fisher CM, Jagsi R, White J. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. Int J Radiat Oncol Biol Phys. 2017 Aug;98(5):1028-35.   PMCID: PMC5572128
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar;97(3):511-5.   PMCID: PMC5485922
Murphy CT, Heller S, Ruth K, Buyyounouski MK, Weinberg D, Uzzo RG, Plimack E, Kutikov A, Chen DY, Horwitz EM. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical radiation oncology. 2015 May;5(3):e215-e222.   PMCID: Needs PMCID
Li J, Lang J, Wang P, Kang S, Lin MH, Chen X, Chen F, Guo M, Chen L, Ma CM. Intensity-modulated radiation therapy for pancreatic and prostate cancer using pulsed low-dose rate delivery techniques. Medical Dosimetry. 2014 Jan;39(4):330-6.
Cohen RJ, Paskalev K, Litwin S, Price RA, Feigenberg SJ, Konski AA. Esophageal motion during radiotherapy: quantification and margin implications. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2010 Aug;23(6):473-9.   PMCID: PMC2933373
Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jan;70(1):59-66.
D'Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer?. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1402-7.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Xu Q, Hamilton RJ, Schowengerdt RA, Alexander B, Jiang SB. Lung tumor tracking in fluoroscopic video based on optical flow. Med Phys. 2008 Dec;35(12):5351-9.
Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007 Jul;68(3):682-9.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. American Journal of Clinical Oncology. 2006 Oct;29(5):458-62.
Konski A, Eisenberg D, Horwitz E, Hanlon A, Pollack A, Hanks G. Does age matter in the selection of treatment for men with early-stage prostate cancer?. Cancer. 2006 May 08;106(12):2598-602 .
Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Aug;66(2):408-15.
Buyyounouski MK, Horwitz EM, Price RA, Hanlon AL, Uzzo RG, Pollack A. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):743-9.
Chen L, Price RA, Wang L, Li J, Qin L, McNeeley S, Ma CM, Freedman GM, Pollack A. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT. International Journal of Radiation Oncology, Biology, Physics. 2004 Oct;60(2):636-47.
Horwitz EM, Feigenberg SJ, Uzzo RG. The treatment of non-metastatic prostate cancer with external beam radiation therapy. Minerva Urologica e Nefrologica. 2004 Jun;56(2):173-88.
Kramer NM, Horwitz EM, Uzzo RG, Hanlon AL, Hanks GE. Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy. BJU international. 2004 Jul;94(1):59-62.
Pawlicki T, Luxton G, Le QT, Findley D, Ma CM. Lens dose in MLC-based IMRT treatments of the head and neck. Int J Radiat Oncol Biol Phys. 2004 May;59(1):293-9.
Wang L, Jacob R, Chen L, Ma C, Movsas B, Feigenberg S, Konski A. Stereotactic IMRT for prostate cancer: setup accuracy of a new stereotactic body localization system. Journal of Applied Clinical Medical Physics. 2004 Jan;5(2):18-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Conformal Radiotherapy

Conformal Radiotherapy Male Prostatic Neoplasms radiotherapy Aged Middle Aged methods Treatment Outcome pathology 80 and over Aged Computer-Assisted Radiotherapy Planning Adult Neoplasm Staging rt [Radiotherapy] Prostate-Specific Antigen blood Radiotherapy Dosage Survival Analysis Female mt [Methods] therapeutic use Human Adenocarcinoma Androgen Antagonists X-Ray Computed Tomography Intensity-Modulated Radiotherapy drug therapy Local Neoplasm Recurrence Cohort Studies Time Factors adverse effects Disease-Free Survival therapy Neoplasm Metastasis Radiation Dosage Radiation Oncology Reproducibility of Results ra [Radiography] prevention & control surgery Imaging Phantoms Radiotherapy Retrospective Studies Movement Prognosis radiation effects Dose Fractionation mortality Magnetic Resonance Imaging Proportional Hazards Models Pancreatic Neoplasms Adjuvant Chemotherapy Risk Assessment bl [Blood] Neoplasm Grading Combined Modality Therapy Kallikreins Nitriles [Instrumentation] drug mo [Mortality] Age Factors epidemiology Esophagus CA-19-9 Antigen high risk Multivariate Analysis Bronchoscopy Tosyl Compounds radiography Breast Neoplasms Reirradiation Adjuvant Chemoradiotherapy mt ae [Adverse Effects] Rectum Taxoids Prostatectomy Incidence Gastrointestinal Diseases Anilides postprostatectomy chemotherapy Intraductal Carcinoma-Noninfiltrating Fibrosis Decision Support Techniques Prospective Studies EC 3-4-21-77 (Prostate-Specific Antigen) etiology Penis is Three-Dimensional Imaging Analysis of Variance adverse Algorithms Quality-Adjusted Life Years US Gov't Support-PHS Ulcerative Colitis Markov Chains Inflammatory Bowel Diseases statistics & numerical data effects Reoperation Antineoplastic Antimetabolites [Methods] US Gov't Support-Non-PHS Neutropenia immunology androgen deprivation instrumentation Gonadotropin-Releasing Hormone diagnosis di [Diagnosis] docetaxel economics chemically induced Equipment Failure Analysis Treatment Failure Physical Examination Re-Irradiation Crystalline Lens Risk Factors Patient Selection Computer-Assisted Radiographic Image Interpretation Biological Tumor Markers Fluoroscopy Lymphatic Metastasis radiation Survival Rate Deoxycytidine Vomiting Statistical Models Automated Pattern Recognition administration & dosage Nausea Adjuvant Radiotherapy Optics and Photonics Health Care Costs Drug Administration Schedule pa [Pathology] Skin Brachytherapy Video Microscopy Prostate Bladder Immobilization dt [Drug Therapy] Tumor Burden complications Hormonal Antineoplastic Agents
Last updated on Wednesday, July 08, 2020